Asset Details
Do you wish to reserve the book?
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
Do you wish to request the book?
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hypomethylating agents increase L1 retroelement expression without inducing novel insertions in myeloid malignancies
2025
Overview
Retroelements in the human genome are silenced via multiple mechanisms, including DNA methylation, to prevent their potential mutagenic effect. Retroelement activity, demonstrated by their expression and somatic retrotransposition events, was shown to be deregulated in multiple tumors but not yet in leukemia. We hypothesized that treatment with hypomethylating agents, commonly used in myelodysplastic syndromes and acute myeloid leukemia, could lead to increased retroelement activity and somatic retrotranspositions, thus contributing to disease progression. To address this hypothesis, we induced the expression of ORF1p protein with hypomethylating agents in DAMI and HL‐60 myeloid cell lines. To study whether long‐term hypomethylating agent therapy induces somatic retrotranspositions, we analyzed (i) both cell lines treated for 4 weeks, and (ii) sequential samples from 17 patients with myelodysplastic syndrome treated with hypomethylating agents. Using a sensitive next‐generation sequencing (NGS)‐based method, no retroelement events were identified. To conclude, we show that although hypomethylating agents induce the expression of LINE‐1‐encoded proteins in myeloid cell lines, de novo somatic retrotransposition events do not arise during the long‐term exposure to these agents.
We investigated whether hypomethylating agents (HMAs) used in myeloid malignancies induce somatic retrotransposition. Our findings indicate that HMA treatment increases L1‐encoded protein expression but does not lead to detectable de novo retrotransposition events in either patient samples or cell lines. This suggests HMAs do not promote new insertional mutagenesis.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Cancer
/ Cells
/ DNA Methylation - drug effects
/ Ethylenediaminetetraacetic acid
/ Genomes
/ Genomics
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ LINE‐1
/ Long Interspersed Nucleotide Elements - drug effects
/ Long Interspersed Nucleotide Elements - genetics
/ Myelodysplastic Syndromes - drug therapy
/ Myelodysplastic Syndromes - genetics
/ Myelodysplastic Syndromes - pathology
/ ORF1p
/ ORF2p
/ Proteins
/ Tumors
